top of page
Try on Wix wlogo v3_wix2small.png

Forging New Paths in Parkinson's Disease Drug Development

Our Mission

At Acurex, our mission is to develop therapeutics that modify the course of Parkinson’s disease, aiming not just to treat symptoms but to alter the disease’s progression fundamentally.

Image by National Cancer Institute

Acurex is supported by funding from Stanford University, the Michael J. Fox Foundation for Parkinson’s Research, The Silverstein Foundation for Parkinson’s with GBA, and The National Institute on Aging.

Brain Scans

Acurex’s platform and founding intellectual property are based on a Stanford University breakthrough discovery enabling the identification of druggable targets that induce biomarker changes in Parkinson's disease (PD). Acurex’s platform has generated two oral small-molecule therapeutic programs that cross the blood-brain barrier and protect PD patient-derived neurons. Acurex’s lead program has begun IND-enabling studies, and the second program to a distinct target is shortly behind. In addition to PD, Acurex has demonstrated value for this approach in other diseases, opening future market opportunities beyond PD and neurodegeneration.

bottom of page